DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema

Recruiting now · Phase 4

Conditions studied: Atopic Dermatitis, Atopic Dermatitis Eczema

In brief

The goal of this randomized controlled trial is to study the (cost)effectiveness of extending the intervals between dupilumab doses in patients with well-controlled atopic eczema, while considering physician- and patient-reported disease severity, quality of life, and dupilumab serum trough levels. Patients will be divided randomly into three groups, receiving dupilumab 300 mg every 2 weeks, every 3 weeks, or every 4 weeks. Researchers will then compare the outcomes among these three groups.

Key facts

Study ID

NCT06004986

Run by

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

People needed

216

Starts

2023-08-14

Expected to finish

2025-12-31

Last updated by the study team

2025-10-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject is an adult,
• Has a diagnosis of AE,
• Receives dupilumab 300 mg q2w for the treatment of AE,
• Has controlled disease according to the Treat-to-Target criteria,
• Agrees to the possibility that the dosage of dupilumab will be lowered,
• Has voluntarily signed and dated an informed consent prior to any study related procedure.

You may not qualify if…

• The subjects uses or initiates another systemic immunomodulating therapy for AE or another diagnosis.

Where it is running

• Amsterdam University Medical Centers — Amsterdam, North Holland, Netherlands (enrolling)
• Erasmus Medical Center — Rotterdam, South Holland, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.